{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAkMSNoKYKDA","lastupdate":"2024-03-13T00:00:00.000Z","update_date":"2024-03-13T00:00:00.000Z","lastModified":"Mar 13, 2024","active":1,"confidence_score":90,"confidence_score_reason":"video or image, markets, not claimed","urlname":"eleven-therapeutics","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$EKgQoGua03t1Lr4oAOyOOCqyntSx0LqVC1UvvJwl3Dv0z0p9plDE0e","name":"Eleven Therapeutics","oneliner":"Next Generation of RNA Therapeutics","registrar":"516183977","website":"https://eleventx.com/","careerspage":"https://eleventx.com/careers/","founded_month":4,"founded_year":2020,"formernames":[],"sociallinks":{"twitter":"https://twitter.com/eleventx?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor","youtube":"","facebook":"","linkedin":"https://www.linkedin.com/company/68800584","instagram":""},"social":["https://twitter.com/eleventx?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor","https://www.linkedin.com/company/68800584"],"flattenedsociallinks":"https://twitter.com/eleventx?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor|https://www.linkedin.com/company/68800584","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":null,"employees":"11-50","employees_exact":28,"patent":1,"raised":25900000,"stage":"Seed","public_stage":"Seed","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["Eleven Tx"],"about":"Eleven Therapeutics is a startup at the forefront of mRNA therapeutics innovation. \n\nThe company’s xRNA modality-based pipeline is aimed to create extended-release mRNA therapeutics (xRNA) targeting unmet medical needs in metabolic, hematologic, and infectious disease areas. TERÅ is a proprietary high-throughput platform designed to screen thousands of xRNA molecules in order to identify non-canonical elements that possess superior stability and safety characteristics, amenable for a multitude of chronic therapeutic applications, including the newly announced fibrotic disorders.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"","country":null,"address":{"israeli":[{"id":"da7492f7-8de3-4344-8d12-ec837c05cd94","city":"Tel Aviv-Yafo","type":null,"address":"Ben Yehuda Street 99, Tel Aviv-Yafo, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":[{"id":"38bfe03d-31e2-43ef-a256-dfe7af3b1115","city":"Boston","address":"Boston, MA, USA","country":"United States","placeid":null},{"id":"859dd564-9b1d-489d-9de5-f58ec15f1757","city":null,"address":"Robinson Way, Cambridge, UK","country":"United Kingdom","placeid":null}]},"headquarter_address":null,"district":"Center District","news":[{"id":"ir2vpfZZd2zXZdpmQEpw5VViVQphoOwyZkoaCl1k8zB6UP6CPvHt1F","date":"Jan 11, 2024","link":"https://www.prnewswire.com/news-releases/eleven-therapeutics-welcomes-dr-paloma-h-giangrande-as-chief-technology-officer-302032421.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Management Changes","company":"Eleven Therapeutics","layoffs":"N/A","summary":"Eleven Therapeutics, a biotechnology company specializing in mRNA therapeutics, has appointed Dr. Paloma H Giangrande as its Chief Technology Officer (CTO). Dr. Giangrande is a leader in the field of nucleic acid therapeutics and has held key leadership roles at renowned biotechnology companies, including Moderna and Wave Life Sciences. In her new role, she will drive the strategic direction for Eleven Therapeutics core xRNA technologies and platforms. The companys CEO, Prof. Yaniv Erlich, expressed his enthusiasm about Dr. Giangrande joining the team, stating that her appointment represents a strategic milestone for the company.","partners":"N/A","customers":"N/A","investors":["Bill & Melinda Gates Foundation"],"confidence":9,"key_topics":["CTO Appointment","mRNA Therapeutics","Nucleic Acid Therapeutics","Leadership","Biotechnology"],"date_of_event":"January 2nd, 2024","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Management Changes"],"acquisition_amount":"N/A","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"XasAJHmFayLcNOvbfiV7AzxaEsbCRl92h33yIzQsXaB4nenarKE8eF","news_summary":"Eleven Therapeutics Welcomes Dr. Paloma H Giangrande as Chief Technology Officer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"56MDcrowDRxzZpRVF6G9qRqykqpykF4nz3jmE9gTujc2BXxJqnkCLn","date":"Jan 9, 2024","link":"https://www.businesskorea.co.kr/news/articleView.html?idxno=209325","source":"www.businesskorea.co.kr","visible":1,"analysis":{"tags":"Partnership, Gene Therapy","company":"Dong-A ST, Eleven Therapeutics","layoffs":"N/A","summary":"South Korean pharmaceutical company Dong-A ST has signed a business agreement with Eleven Therapeutics to develop RNA-based gene therapies. The partnership will focus on discovering RNA therapies for fibrotic diseases using Eleven Therapeutics TERA platform technology, which uses AI and machine learning to decode high-throughput RNA chemical modifications. This collaboration aligns with Dong-A STs strategy of expanding its R&D capabilities in the field of gene therapy.","partners":"Eleven Therapeutics","customers":"N/A","investors":"N/A","confidence":9,"key_topics":"RNA Therapies, Fibrotic Diseases, TERA platform, Gene Therapy, Partnership","date_of_event":"2024.01.10","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Partners, Expand","acquisition_amount":"N/A","structuredIssuesShow":"#Partners, Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"VWfXXZXBTfpiJyrI3heSsKfR5spdY15G4XDyECtR0o5dVhrbwzIsUG","news_summary":"Dong-A ST Signs R&D Agreement with Eleven Therapeutics for RNA-based Gene Therapy","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"dhPi2IkNxmkTKTK5ZKzfVqfqpJFce5UnoHAKBs5QYvkpeG4edUOGwx","date":"Jul 16, 2023","link":"https://www.pharmaceutical-technology.com/news/eleven-novo-nordisk-partner-develop-nucleic-acid-therapeutics/","source":"www.pharmaceutical-technology.com","visible":1,"analysis":{"tags":"Partnership, Drug Discovery","company":"Eleven Therapeutics, Novo Nordisk","layoffs":"Not mentioned","summary":"Eleven Therapeutics and Novo Nordisk have announced a research partnership to identify novel nucleic acid molecules to treat cardiometabolic diseases using Eleven’s DELiveri platform. The DELiveri platform uses AI and machine learning in combination with DNA-encoded libraries to find conjugates that can transport therapeutic molecules. Novo Nordisk will have exclusive rights to specific cell types and applications developed using the DELiveri platform. This partnership is part of a series of investments made by Novo Nordisk, including an expansion of its manufacturing facilities in Denmark and a partnership with Aspect Biosystems.","partners":"Microsoft, Aspect Biosystems","customers":"Not mentioned","investors":"Novo Nordisk","confidence":9,"key_topics":"Research Partnership, Cardiometabolic Diseases, DELiveri Platform, AI, Drug Discovery","date_of_event":"September 2022","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Partners, Investment","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Partners, Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"RrNvR3vdYdnXsHmsChrPhDsMKHPSWqvCYuK0SPiHLRVJjiYsSzrrX5","news_summary":"Eleven and Novo Nordisk partner to develop nucleic acid therapeutics - Pharmaceutical Technology","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"jf1Kz4Y2DoJFiDfkXNAnn4buJQ7BhdxsJZTaIkI5HM2VV4VlCuKFNH","date":"Mar 26, 2023","link":"https://www.calcalistech.com/ctechnews/article/rjies1flh","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"Conference Speech","company":"Eleven Therapeutics","layoffs":null,"summary":"Yaniv Erlich, CEO of Eleven Therapeutics, spoke at the Mind the Tech conference in London, stating that his company is revolutionizing the world of RNA. The conference, which is an annual event by Calcalist, focused on the changes experienced by the high-tech sector over the past year. It assessed the impact of market shakeups on the high-tech economy and reviewed upcoming trends in the technology world.","partners":[],"customers":[],"investors":[],"confidence":8,"key_topics":["RNA Revolution","Mind the Tech Conference","High-Tech Sector","Market Shakeup","Technology Trends"],"date_of_event":"2023","valuation_amount":null,"impact_on_company":"Growth-Positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"sMrTvJ0JTqvmKYUkV0hcHvWNm8YNTW6Qh4PTPsm01uScVuryIpSQGW","news_summary":"\"We are revolutionizing the world of RNA\" | CTech","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"8d5abb57-5cdf-4b81-9100-f0668d1b3edd","date":"Aug 2, 2022","link":"https://www.finsmes.com/2022/08/eleven-therapeutics-raises-22m-in-seed-funding.html","source":"www.finsmes.com","visible":1,"analysis":{"tags":"biotechnology, seed funding","company":"Eleven Therapeutics","layoffs":null,"summary":"Eleven Therapeutics, a biotechnology company focused on advancing nucleic acid therapeutics, has raised $22 million in seed funding. The funding includes a $9 million commitment from the Bill and Melinda Gates Foundation, with $5 million towards future equity investment and $4 million as a non-dilutive grant. The funding will support the development of a platform that designs small interfering RNAs (siRNAs) with ultra-long durability. Eleven Therapeutics aims to develop siRNA treatments for respiratory diseases using its flagship invention, SCSI-RNA™. The company has collaborative hubs in Cambridge, UK; Boston, US; and Tel Aviv, Israel. The funding will also promote wide accessibility of Elevens treatments to people in need in developing countries.","partners":null,"customers":null,"investors":["Bill and Melinda Gates Foundation","Kindred Capital","NFX Bio","Harel Technology Investments","Entrée Capital","Innovate UK Smart Grant"],"confidence":9,"key_topics":["Eleven Therapeutics","seed funding","Bill and Melinda Gates Foundation","nucleic acid therapeutics","siRNAs"],"date_of_event":"02/08/2022","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$22 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"GQ4MLKTROFCtpi6PQuoe7CrDhRTBodgyfhgrCOvZfoQgb9TJhYIJ9o","news_summary":"Eleven Therapeutics Raises $22M in Seed Funding - FinSMEs","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"aea205d3-40c7-4454-9bb3-7c9ce5dcdd9c","date":"Feb 7, 2022","link":"https://www.biospace.com/article/releases/twist-bioscience-and-eleven-therapeutics-create-replicon-for-development-of-antiviral-tools/","source":"www.biospace.com","visible":1,"analysis":{"tags":["viral genome replication","antiviral drug screening","vaccine and therapeutic development"],"company":"Twist Bioscience Corporation","layoffs":null,"summary":"Twist Bioscience and Eleven Therapeutics have developed a replicon tool for studying viral genome replication and antiviral drug screening, as well as vaccine and therapeutic development. The replicon is a synthetic viral RNA molecule that mimics viruses but has been engineered to remove the infectious portion of the genome. The teams demonstrated the development of a safe and efficient SARS-CoV-2 replicon-generating engine. The replicon can be used to study viral activity without the need for patient samples or handling live virus. The replicon system is flexible and can be used to produce other variants of the virus. Twist Bioscience and Eleven Therapeutics are leveraging synthetic biology to complement efforts in developing therapies and interventions for future variants of concern.","partners":["Eleven Therapeutics"],"customers":null,"investors":null,"confidence":8,"key_topics":["Replicons","SARS-CoV-2","therapeutic development","variant characteristics","synthetic biology"],"date_of_event":"2022-02-07","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"LfYaco9tk0EURlOt7qHJ13KdAfaY9IMF30N4nW8Gw2sJK5TJWvxuLq","news_summary":"Twist Bioscience and Eleven Therapeutics Create Replicon for Development of Antiviral Tools  BioSpace","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":6,"techcommunityinvolvement":null,"mediagallery":[],"tags":["respiratory","artificial-intelligence","drug-development","molecular-biology","pharma-companies","therapeutics"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"R&D","products":["SCSI-RNA"],"geomarkets":[],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":3,"lastfunding":"$22M","totalrounds":3,"fundingstage":"Seed","totalfunding":"$25.9M","publicinvestors":3,"lastpublicfunding":22000000,"totalpublicrounds":3,"totalpublicfunding":25900000},"team":[{"name":"Prof. Yaniv  Erlich","email":"yaniv@eleventx.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAkJTQv-cKDA","bounced":false,"claimed":0,"founder":1,"urlname":"yaniv-erlich","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICQ5PG2xwgM","position":"Co-founder & CEO","last_name":"Erlich","claimtoken":"UkO4iCQxCqoEJPSjK1VUDbvmoiZ4679IqzXi72wYNNneo3cmp6dT9u","first_name":"Prof. Yaniv ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/yaniv-erlich-78321640/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2024-03-13 13:39:34.000000","initials":"PE","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Prof. Greg Hannon","email":"greg@eleventx.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAkMSt8qoJDA","bounced":true,"claimed":0,"founder":1,"urlname":"prof-greg-hannon","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICQlI3GiQoM","position":"Co-founder & Director of Cancer Research UK, University of Cambridge","last_name":"Hannon","claimtoken":"a125c9a26e764d376d5eb0a7a86402f263d47f92d1f0e75d4a80e946bab57b48","first_name":"Prof. Greg","picturekey":null,"claimeddate":null,"linkedinurl":null,"unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":null,"initials":"PH","pictureurl":"/assets/empty-state.svg","linkedin-display":"none","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Shaul Ilan","email":"shaul@eleventx.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAkMTykLsJDA","bounced":false,"claimed":0,"founder":1,"urlname":"shaul-ilan-1","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICQxLDc2QoM","position":"Co-founder, COO & Business Development","last_name":"Ilan","claimtoken":"AYXmQGaAbHJYaxo1AnxekvSKru7Mi2G0IJg6mlDNxKzoqC4JVcok8s","first_name":"Shaul","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/shaul-ilan-8064bb51/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2024-03-13 13:39:27.000000","initials":"SI","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Iris  Grossman","email":"iris@eleventx.com","phone":"","gender":"Female","userid":"DuLM3LgUeTkLOtI6Vxz97VVJTbyOzf6x470PtIyTRCeX2W28AKcpRn","bounced":false,"claimed":null,"founder":0,"urlname":"iris-grossman","visible":1,"memberid":"oIHU0SZcjHTZP6OylfiuQdTqv9AxraIhXQMkYnwEY7LyDj35ip0Q79","position":"Chief Therapeutics Officer","last_name":"Grossman","claimtoken":"QOZ788s6i5woUmE5zUHP0wZZ0KMXeUWnVjZDdEr4Z49vdE8gWe7tsR","first_name":"Iris ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/irisgrossman/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2024-03-13 13:18:57.000000","initials":"IG","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Pharmaceuticals","sectorverify":null,"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoNqyo8cLDA","fullname":"Yotam Maman"},"biverifydate":"2022-02-08T00:00:00.000Z","crunchbaseid":"","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":"Yotam Maman","creator_email":"yotamm1988@gmail.com","createdate":"2022-02-08T00:00:00.000Z","biverification":"Yotam Maman","sectorverification":null,"affiliatedOrganizations":null,"timeline":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJDEzoHkCww","date":"Aug 2022","amount":"$22M","source":"https://entreecap.com/companies?sectorshealth---life-sciences, https://eleventx.com/, , https://www.linkedin.com/in/omri-amirav-drory-50572727/, https://www.calcalistech.com/ctechnews/article/h1ju600ltc","eventtype":"FundingRoundEvent","investment":[{"name":"NFX Capital","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/nfx-guild1","logokey":"$wyFW415Hl7g4xa3CX4uzm5VjA6wcovghFNMwaB46FtfD9vlqyR2iuC","tagline":null,"urlname":"/investor_page/nfx-guild1","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4KTEh9IIDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"1c7f1d7d-5d72-4135-9b32-c8001be2480c","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$wyFW415Hl7g4xa3CX4uzm5VjA6wcovghFNMwaB46FtfD9vlqyR2iuC","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"Harel Insurance & Finance","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/harel-insurance-finance","logokey":"$eer3trCbMymhkw74aHRrv9S0RWCWy2WY5QqJwAgg20sbhhQTXZrk0k","tagline":null,"urlname":"/investor_page/harel-insurance-finance","isisraeli":1,"investorid":"7IA52i2eTfWfJysCrQqMc9KYgUk2NiYwEDYRYWntmIvgUwfrOmjt2F","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"IMlzfTkUQZ6UQB2XUfKU0OGyPlqZn5mr2diteFfHyVIwqPu5OsYImC","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$eer3trCbMymhkw74aHRrv9S0RWCWy2WY5QqJwAgg20sbhhQTXZrk0k","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":22000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJDqxO6lCgw","date":"Jun 2021","amount":"$3.9M","source":"https://medium.com/@eleventx/eleven-therapeutics-receives-3-9-e76c32eee9b7","eventtype":"GrantEvent","granttype":1,"investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":3900000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJCkvLqCCgw","date":"Sep 2020","amount":"Undisclosed","source":"https://entreecap.com/companies?sectors=health---life-sciences","eventtype":"FundingRoundEvent","investment":[{"name":"Entrée Capital","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/entr-e-capital","logokey":"$hGR2j5fYNcPTG4toUBBdxEi1bamaVcEXUqC4URRp6O9Ipv6S4shHjZ.png","tagline":null,"urlname":"/investor_page/entr-e-capital","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgNmJ7oMJDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"79bf219c-cfc2-4b71-b9d6-a60ce2d2dbd7","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$hGR2j5fYNcPTG4toUBBdxEi1bamaVcEXUqC4URRp6O9Ipv6S4shHjZ.png","leadcaption":"Lead ","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Pre-Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"4/2020","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Eleven Therapeutics","logourl":"https://storage.googleapis.com/clean-finder-353810/$EKgQoGua03t1Lr4oAOyOOCqyntSx0LqVC1UvvJwl3Dv0z0p9plDE0e","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$EKgQoGua03t1Lr4oAOyOOCqyntSx0LqVC1UvvJwl3Dv0z0p9plDE0e","seoabout":"Eleven Therapeutics is a startup at the forefront of mRNA therapeutics innovation. \n\nThe company’s xRNA modality-based pipeline is aimed to create extended...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":4,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Artificial Intelligence","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"},{"depth":3,"name":"Biotechnology","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","TechnologyClassificationModel>Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"},{"title":"Biotechnology","key":"0-0-0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Biotechnology"}]}]}],"coreTechnology":[{"title":"Artificial Intelligence","key":"0-0","path":"TechnologyClassificationModel>Artificial Intelligence"}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Artificial Intelligence","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"},{"depth":3,"name":"Biotechnology","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development"],"coreTechnology":["Artificial Intelligence"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Pharmaceuticals","Biotechnology"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJDEzoHkCww","date":"Aug 2022","amount":"$22M","source":"https://entreecap.com/companies?sectorshealth---life-sciences, https://eleventx.com/, , https://www.linkedin.com/in/omri-amirav-drory-50572727/, https://www.calcalistech.com/ctechnews/article/h1ju600ltc","eventtype":"FundingRoundEvent","investment":[{"name":"NFX Capital","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/nfx-guild1","logokey":"$wyFW415Hl7g4xa3CX4uzm5VjA6wcovghFNMwaB46FtfD9vlqyR2iuC","tagline":null,"urlname":"/investor_page/nfx-guild1","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4KTEh9IIDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"1c7f1d7d-5d72-4135-9b32-c8001be2480c","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$wyFW415Hl7g4xa3CX4uzm5VjA6wcovghFNMwaB46FtfD9vlqyR2iuC","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"Harel Insurance & Finance","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/harel-insurance-finance","logokey":"$eer3trCbMymhkw74aHRrv9S0RWCWy2WY5QqJwAgg20sbhhQTXZrk0k","tagline":null,"urlname":"/investor_page/harel-insurance-finance","isisraeli":1,"investorid":"7IA52i2eTfWfJysCrQqMc9KYgUk2NiYwEDYRYWntmIvgUwfrOmjt2F","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"IMlzfTkUQZ6UQB2XUfKU0OGyPlqZn5mr2diteFfHyVIwqPu5OsYImC","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$eer3trCbMymhkw74aHRrv9S0RWCWy2WY5QqJwAgg20sbhhQTXZrk0k","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":22000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJCkvLqCCgw","date":"Sep 2020","amount":"Undisclosed","source":"https://entreecap.com/companies?sectors=health---life-sciences","eventtype":"FundingRoundEvent","investment":[{"name":"Entrée Capital","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/entr-e-capital","logokey":"$hGR2j5fYNcPTG4toUBBdxEi1bamaVcEXUqC4URRp6O9Ipv6S4shHjZ.png","tagline":null,"urlname":"/investor_page/entr-e-capital","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgNmJ7oMJDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"79bf219c-cfc2-4b71-b9d6-a60ce2d2dbd7","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$hGR2j5fYNcPTG4toUBBdxEi1bamaVcEXUqC4URRp6O9Ipv6S4shHjZ.png","leadcaption":"Lead ","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Pre-Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJDqxO6lCgw","date":"Jun 2021","amount":"$3.9M","source":"https://medium.com/@eleventx/eleven-therapeutics-receives-3-9-e76c32eee9b7","eventtype":"GrantEvent","granttype":1,"investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":3900000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"merger_acquisitions":[],"others":[]}}